Key Points
- CEO Xingjuan Chao sold 39,000 shares on April 6 at an average price of $18.40 for $717,600, trimming her stake by 4.39% to 850,347 shares; the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- CeriBell beat quarterly estimates with EPS of ($0.36) vs. ($0.43) and revenue of $24.78M, but remains unprofitable with negative margins and a negative PE; the stock trades near $18.68 with a 52‑week range of $10.01–$24.33 and a market cap of about $703M.
- Analysts hold a consensus Moderate Buy rating with a $23.20 price target, and several institutional investors — notably Bank of New York Mellon — have significantly increased their positions recently.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 39,000 shares of the business's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $18.40, for a total value of $717,600.00. Following the transaction, the chief executive officer directly owned 850,347 shares in the company, valued at $15,646,384.80. This trade represents a 4.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xingjuan Chao also recently made the following trade(s):
- On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $17.45, for a total value of $680,550.00.
- On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total value of $41,242.36.
CeriBell Price Performance
CBLL opened at $18.68 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The stock has a market capitalization of $703.12 million, a PE ratio of -12.71 and a beta of 0.94. The stock's 50 day moving average price is $19.12 and its 200-day moving average price is $17.58.
CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to analysts' expectations of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. On average, equities research analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.
Analyst Upgrades and Downgrades
CBLL has been the topic of several recent research reports. BTIG Research reaffirmed a "buy" rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. Canaccord Genuity Group upped their price target on CeriBell from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of CeriBell in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.20.
View Our Latest Stock Analysis on CeriBell
Institutional Investors Weigh In On CeriBell
Several hedge funds have recently added to or reduced their stakes in CBLL. Bank of New York Mellon Corp boosted its holdings in CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company's stock worth $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc bought a new position in shares of CeriBell during the fourth quarter valued at $21,930,000. Royce & Associates LP bought a new position in shares of CeriBell during the fourth quarter valued at $11,695,000. Adage Capital Partners GP L.L.C. bought a new position in shares of CeriBell during the fourth quarter valued at $10,965,000. Finally, CenterBook Partners LP lifted its holdings in shares of CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company's stock valued at $5,476,000 after purchasing an additional 389,584 shares in the last quarter.
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
